Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
about
Capecitabine for ER-positive versus ER-negative breast cancerTiming and extent of response in colorectal cancer: critical review of current data and implication for future trialsAdjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineNeoadjuvant therapy in the treatment of breast cancerAGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials.Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials.Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trialSecond-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancerFilling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials.Acute Inflammatory Response During Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Case ReportGross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypesThe relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.NEO adjuvant chemotherapy in breast cancer: What have we learned so far?Breast Cancer 2012 - New AspectsBoth carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review.Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer.Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention studyQuality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy.Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.Locoregional therapy of locally advanced breast cancer: a clinical practice guideline.Review of breast conservation therapy: then and nowComparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer.Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts.Neoadjuvant therapy for locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments' armamentarium.Triple-negative breast cancer: an update on neoadjuvant clinical trials.Neoadjuvant Therapy - What Have We Achieved in the Last 20 Years?A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast CancerA Phase II Study of Concurrent Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer.Efficacy of vinorelbine-based neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis of randomized controlled trials.Preoperative Systemic Treatment in BRCA-Positive Breast Cancer Patients: Case Report and Review of the Literature.Polymorphisms in genes involved in drug detoxification and clinical outcomes of anthracycline-based neoadjuvant chemotherapy in Chinese Han breast cancer patients.Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast CancerCapecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials.Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer.A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial.Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival.
P2860
Q24194664-8242A73B-A813-47D0-8719-915E061F2D24Q26797292-4D34BBE1-5DCF-453E-9249-59AE3CA79CC6Q26853619-D0BF9000-8852-4208-815D-DF3A660670B5Q27694514-893815DD-62D3-447B-A351-5108E21AD034Q30318240-1AC8B2DF-AF6E-46B5-99A8-458615530A8BQ30588206-B981FD1E-5934-40AF-A0F8-356618472E25Q30976616-473299F2-2798-4D82-ACB7-98C137A562ADQ31050387-A85CB7F8-90B3-46C9-8E48-15FA8A1A306FQ33394310-634B1928-F49F-4D07-99E7-203D65846A09Q33659628-0B1FBE4E-F9F6-43AB-B786-1C4220CFB6B7Q33785011-802AD961-E541-4442-A613-2F683523F518Q33888580-F51FD760-CCAF-46CF-B9CD-BE44CA612D85Q34006749-3B5608D6-68E9-4E90-8325-CFAE39AFAC8CQ34075789-107E0E5B-0E74-4220-8371-E54CBCB8E85AQ34138174-DB2FA629-167A-4A51-9B2D-88DEB1F29AAAQ34209663-A8C37C5F-5A75-420E-9EA3-E2832F6A736EQ34232366-080CC31B-5FEB-47DB-ADDD-5F3F0056B0E9Q34415629-11D2702B-ADC7-4FD8-8CFF-CF303968FDC8Q34440998-95631D66-C8E6-4F66-A067-9C766D2CCF78Q34520174-5B299703-158F-4DA8-B2E8-D213708490D5Q34816825-5EA86485-E72A-45DA-8143-8E79EF231280Q35060987-806F452A-9BC0-41C2-AAF9-F4BBDE8B0AFCQ35239625-8335D079-2796-46E3-A5FF-4F52E5EC71EBQ35433289-EF018094-CC2B-4EE5-A417-39BD70958DAEQ35435580-79F5DDF4-0E43-45ED-8184-E63681B89393Q35450768-38B43FCA-77A8-4647-9D8A-A00A633E2549Q35576250-72F2E956-0D1F-4D3D-B09D-C780A2811326Q35667692-5C238C88-52E0-439A-83E2-2F5E6C0CA7BCQ35725961-99DD9F27-94B1-40A4-AEE1-356BE9C920A4Q35789457-F70877A1-CC33-462D-A70F-0EC4B8EA1893Q35862343-187B2497-CBD9-49A9-814F-DDEA75C0CDC9Q35872171-3AC59BD2-92A9-4026-AE84-39E419ECD557Q35954081-C3F5A4DA-73CB-490F-A1B9-8222B04C5C3EQ35976084-7CDBFA40-32C2-41A3-AFF4-3854B7E7F09CQ36009708-1F7D753D-9A69-4929-8FE3-410F0807319CQ36084852-73D3450B-0BA4-49DA-B768-786889EDF1E5Q36163866-3C0379B4-CB8A-4EC3-B1D1-9B5EE63FF425Q36419147-D812006A-C7AC-4803-9CFF-CCB02AF2FEBCQ36663561-0AB54DF3-4B38-4454-A371-B508BBA95D74Q36848102-6DFECDE9-3D44-4960-9450-E80250B03599
P2860
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Neoadjuvant vinorelbine-capeci ...... II randomized GeparTrio trial.
@en
Neoadjuvant vinorelbine-capeci ...... II randomized GeparTrio trial.
@nl
type
label
Neoadjuvant vinorelbine-capeci ...... II randomized GeparTrio trial.
@en
Neoadjuvant vinorelbine-capeci ...... II randomized GeparTrio trial.
@nl
prefLabel
Neoadjuvant vinorelbine-capeci ...... II randomized GeparTrio trial.
@en
Neoadjuvant vinorelbine-capeci ...... II randomized GeparTrio trial.
@nl
P2093
P356
P1476
Neoadjuvant vinorelbine-capeci ...... II randomized GeparTrio trial.
@en
P2093
Bernd Gerber
Christian Jackisch
Claus Hanusch
German Breast Group
Gunter von Minckwitz
Holger Eidtmann
Jens Huober
Jörn Hilfrich
Keyur Mehta
Manfred Kaufmann
P304
P356
10.1093/JNCI/DJN085
P407
P577
2008-04-08T00:00:00Z